A Phase 1 Study of PF-07799544 Plus PF-07799933 in People With BRAF V600-Mutated Advanced Melanoma

Full Title

Phase 1A/B Open-Label Master Study of PF 07799544 as a Single Agent and in Combination with other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors

Purpose

Researchers want to find the best doses of PF-07799544 and PF-07799933 to use in people with advanced melanoma. The people in this study have melanoma that has metastasized (spread) and has a mutation (change) in the BRAF gene.

PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Monica Chen’s office at 646-888-5108.